Customize your search results with filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.

Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant: A case report.

Targeted therapy for treatment of patients with classical hairy cell leukemia.

How we treat mature B-cell neoplasms (indolent B-cell lymphomas).

Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial.

Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up.

The pharmacological management of hairy cell leukemia.

Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.

Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis.

Mastocytosis onset in a patient with treated hairy cell leukemia: Just a coincidence?

Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia.

Showing 1-12 of 18